三价多克隆抗体(trimodulin)治疗重症社区获得性肺炎的疗效与安全性:随机、安慰剂对照、双盲、多中心Ⅱ期试验(CIGMA研究)
CIGMA研究为双盲、多中心Ⅱ期试验,纳入160例需要侵入性机械通气的重症社区获得性肺炎患者,按1:1随机接受trimodulin(42 mg IgM/kg/day)或安慰剂,连续5天。主要终点无呼吸机天数在trimodulin组(均值11.0,中位数11,n=81)与安慰剂组(均值9.6,中位数8,n=79)间无统计学显著差异(p=0.173)。28天全因死亡率分别为22.2%与27.8%(p=0.465),不良事件发生率相当。事后亚组分析(覆盖58–78%患者)显示,基线高CRP、低IgM及高CRP/低IgM患者中trimodulin组全因死亡率显著降低。作者认为这些发现值得进一步研究。
要点
- 在需要侵入性机械通气的重症社区获得性肺炎患者中,trimodulin(42 mg IgM/kg/day,连续5天)与安慰剂相比,无呼吸机天数无统计学显著差异(均值11.0 vs 9.6,p=0.173)。
- 28天全因死亡率trimodulin组22.2% vs 安慰剂组27.8%,差异无统计学显著(p=0.465)。
- 事后亚组分析显示,基线高CRP、低IgM及高CRP/低IgM患者中trimodulin组全因死亡率显著降低,该分析覆盖58–78%的患者。
- 两组不良事件发生率相当,安全性与耐受性监测未见差异。
- 作者结论:总体无显著差异,事后分析支持特定亚组可能获益,需进一步研究。
适用人群与场景
- 需要侵入性机械通气的重症社区获得性肺炎(sCAP)患者,共160例随机分组。
处置流程与药物剂量
- trimodulin组:trimodulin 42 mg IgM/kg/day,连续5天,作为 add-on 治疗;对照组:安慰剂。
- 给药途径原文未写明。
研究设计与关键结果
- 研究类型:随机、安慰剂对照、双盲、多中心Ⅱ期试验(NCT01420744),样本量160例,纳入需要侵入性机械通气的sCAP患者。
- 主要终点无呼吸机天数(VFDs):trimodulin组均值11.0、中位数11(n=81) vs 安慰剂组均值9.6、中位数8(n=79),p=0.173,无统计学显著差异。
- 28天全因死亡率:trimodulin组22.2% vs 安慰剂组27.8%,p=0.465,无统计学显著差异;肺炎相关死亡率原文未报告具体数值。
- ICU转出时间及平均住院时长两组相当;不良事件发生率两组相当。
- 事后亚组分析(覆盖58–78%患者):基线高CRP(≥70 mg/L)、低IgM(≤0.8 g/L)及高CRP/低IgM患者中,trimodulin组较安慰剂组全因死亡率显著降低。
证据类型、等级与局限
- 证据类型:随机、安慰剂对照、双盲、多中心Ⅱ期试验。
- 试验注册号:NCT01420744。
- 局限:作者结论指出这些发现需进一步研究(warrant further investigation);事后亚组分析为探索性分析。
对床旁实践的改变
- 作者认为,事后分析支持trimodulin在高CRP、低IgM或两者兼有的sCAP患者中可能改善死亡率结局,但总体人群无显著差异,需进一步研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: The CIGMA study investigated a novel human polyclonal antibody preparation (trimodulin) containing ~ 23% immunoglobulin (Ig) M, ~ 21% IgA, and ~ 56% IgG as add-on therapy for patients with severe community-acquired pneumonia (sCAP).
METHODS: In this double-blind, phase II study (NCT01420744), 160 patients with sCAP requiring invasive mechanical ventilation were randomized (1:1) to trimodulin (42 mg IgM/kg/day) or placebo for five consecutive days. Primary endpoint was ventilator-free days (VFDs). Secondary endpoints included 28-day all-cause and pneumonia-related mortality. Safety and tolerability were monitored. Exploratory post hoc analyses were performed in subsets stratified by baseline C-reactive protein (CRP; ≥ 70 mg/L) and/or IgM (≤ 0.8 g/L).
RESULTS: Overall, there was no statistically significant difference in VFDs between trimodulin (mean 11.0, median 11 [n = 81]) and placebo (mean 9.6; median 8 [n = 79]; p = 0.173). Twenty-eight-day all-cause mortality was 22.2% vs. 27.8%, respectively (p = 0.465). Time to discharge from intensive care unit and mean duration of hospitalization were comparable between groups. Adverse-event incidences were comparable. Post hoc subset analyses, which included the majority of patients (58-78%), showed significant reductions in all-cause mortality (trimodulin vs. placebo) in patients with high CRP, low IgM, and high CRP/low IgM at baseline.
CONCLUSIONS: No significant differences were found in VFDs and mortality between trimodulin and placebo groups. Post hoc analyses supported improved outcome regarding mortality with trimodulin in subsets of patients with elevated CRP, reduced IgM, or both. These findings warrant further investigation.
TRIAL REGISTRATION: NCT01420744.
参考来源
- Welte T, Dellinger RP, Ebelt H, et al. Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study). Intensive Care Med. 2018. PMID: 29632995. doi:10.1007/s00134-018-5143-7
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。